<scp>JAK</scp> Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by <scp>CTLA</scp>‐4 and <scp>PD</scp>‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report
In cases where immune-related colitis proves resistant to treatment with glucocorticoids, infliximab, or tacrolimus, upadacitinib represents a potential option as a JAK inhibitor.
Authors
- George Tribonias
- Hisato Kawakami (ORCID: https://orcid.org/0000-0002-3280-4850)
- Yoriaki Komeda (ORCID: https://orcid.org/0000-0002-0068-8461)
- Kohei Handa
- Shunsuke Omoto (ORCID: https://orcid.org/0000-0001-7291-3608)
- Satoru Hagiwara (ORCID: https://orcid.org/0000-0002-3412-4701)
- Masatoshi Kudo (ORCID: https://orcid.org/0000-0002-4102-3474)
- Hiroshi Kashida (ORCID: https://orcid.org/0000-0002-7186-600X)
- Masashi Kono (ORCID: https://orcid.org/0000-0002-3026-1311)
- Mamoru Takenaka (ORCID: https://orcid.org/0000-0001-7308-4311)
- Naoko Tsuji (ORCID: https://orcid.org/0000-0003-2699-2071)
Institutions
- Red Cross Hospital (GR)
- Kindai University (JP)
Publication Details
- Journal
- Cancer Reports
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/cnr2.70032
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13